The Global Nasal Drug Delivery Systems Market accounted for US$ 51.20 billion in 2020 and is estimated to be US$ 92.47 billion by 2030 and is anticipated to register a CAGR of 6.1%. Nasal drug delivery is most preferred route of administration in treatment of allergic and non-allergic rhinitis, nasal congestion, and common cold. Intranasal route can be cross the blood brain barrier and deliver the drug molecules to the central nervous system. The drugs are also been administered via nasal route for therapeutic and recreational purpose, with the help of nasal drug delivery systems. Nasal drug delivery is advisable for drugs undergoing extensive first pass effect. Further, intranasal route is also exploited for bypassing the blood brain barrier and delivery the drugs molecules to the central nervous system. The nasal drug delivery systems are different for different drug, depending on their formation, as liquid nasal preparations are administered through inhalers, droppers, spray pumps,